Cardiovascular Event Prevention in the Person With Type 2 Diabetes

Abstract

Get full access to this article

View all access options for this article.

References

Kannel WB

McGee DL.

Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241: 2035-2038.

Manson JE

Colditz GA

Stampfer MJ

et al.

A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151: 1141-1147.

Haffner SM

Lehto S

Ronnemaa T

et al.

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339: 229-234.

Chobanian AV

Bakris GL

Black HR

et al.

The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (the JNC 7 Report). JAMA. 2003;289: 2560-2571.

National Cholesterol Education Panel

. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: www.nhlibi.nih.gov/guidelines/cholesterol 2004. Accessed November 18, 2004.

Beckman JA

Creager MA

Libby P.

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287: 2570-2581.

Gaede P

Vedel P

Larsen N

et al.

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348: 383-393.

American Diabetes Association

. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl): S4-S36.

Geiss LS

Herman WH

Smith PJ.

Mortality in non-insulin dependent diabetes. In:

National Diabetes Data Group

, eds. Diabetes in America. Washington, DC: National Institute of Diabetes and Digestive and Kidney Diseases; 1995:233-257.

10.

Reaven G.

Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106: 286-288.

11.

World Health Organization

. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Geneva, Switzerland: WHO Department of Noncommunicable Disease Surveillance; 1999.

12.

Kahn R

Buse J

Ferrannini E

et al.

The metabolic syndrome: time for a critical reappraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28: 2289-2304.

13.

Diamond FB

Eichler DC.

Leptin and the adipocyte endocrine system. Crit Rev Clin Lab Sci. 2002;39: 499-525.

14.

ATP III Coronary Heart Disease risk categories. 2005. Available at: http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=pub.

15.

National Heart, Lung, and Blood Institute

. Framingham risk score calculations. 2005. Available at: www.nhlbi.nih.gov/about/framingham/riskabs.htm.

16.

Fransilla-Kallunki A

Rissanen A

Ekstrand A

et al.

Weight loss by very-low-calorie diets: effects on substrate oxidation, energy expenditure, and insulin sensitivity in obese subjects. Am J Clin Nutr. 1992;56(suppl 1): 247S-248S.

17.

DeFronzo RA

Sherwin RS

Kraemer N.

Effect of physical training on insulin action in obesity. Diabetes. 1987;36: 1379-1385.

18.

Diabetes Prevention Program Study Group

. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes. 2005;54: 1150-1156.

19.

National Institutes of Health

. Look AHEAD: action for health in diabetes. Available at: www.niddk.nih.gov/patient/SHOW/lookahead//htm 2005.

20.

Levetan CS

Dawn KR

Robbins DC

et al.

Impact of computer-generated personalized goals on HbA1c. Diabetes Care. 2002;25: 2-8.

21.

Turner RC

Millns H

Neil HAW

et al.

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ. 1998; 316: 823-828.

22.

Pyorala K

Pedersen TR

Kjekshus J

et al.

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20: 614-620.

23.

Kornowski R

Goldbourt U

Zion M

et al.

Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. SPRINT Study Group. Am J Cardiol. 1993;72: 883-888.

24.

Kirpichnikov D

McFarlane SI

Sowers JR.

Metformin: an update. Ann Intern Med. 2002;137: 25-33.

25.

Chu NV

Kong AP

Kim DD

et al.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25: 542-549.

26.

Gilling L

Suwattee P

DeSouza C

et al.

Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs. 2002;2: 143-156.

27.

Natali A

Baldeweg S

Toschi E

et al.

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetics. Diabetes Care. 2004;27: 1349-1357.

28.

Satoh N

Ogawa Y

Usui T

et al.

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26: 2493-2499.

29.

Fonarow GC.

Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J. 2004; 148: 551-558.

30.

Wright A

Burden AC

Paisey RB.

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 year in patients with type 2 diabetes in the UK Prospective Diabetes Study. Diabetes Care. 2002; 25: 330-336.

31.

Campbell IW.

The clinical significance of PPAR gamma agonism. Curr Mol Med. 2005;5: 349-363.

32.

Ovalle F

Bell DS.

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4: 56-59.

33.

Cook MN

Girman CJ

Stein PP

et al.

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28: 995-1000.

34.

Grundy SM

Cleeman JI

Merz CN

et al.

Implications of recent clinical trials for the National Cholesterol Education Panel Adult Treatment Panel III guidelines. Circulation. 2004;110: 227-239.

35.

LaRosa JC

Grundy SM

Waters DD

et al.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352: 1425-1435.

36.

Brunzell JD

Hokanson JE.

Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22(suppl 3): C10-C13.

37.

Lawrence JM

Reid J

Taylor GJ

et al.

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfraction in overweight patients with early type 2 diabetes. Diabetes Care. 2004;27: 41-46.

38.

Rubins HB

Robins SJ

Collins D

et al.

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341: 410-418.

39.

Adler AI

Stratton IM

Neil HA

et al.

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective, observational study. BMJ. 2000;321: 412-419.

40.

Hanson L

Zanchetti A

Carruthers SG

et al.

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351: 1755-1762.

41.

deCotret PR.

Relationships among diabetes, microalbuminuria, and ACE inhibition. J Cardiovasc Pharmacol. 1998;32(suppl 2): S9-S17.

42.

Parving H-H

Lehnert H

Brochner-Mortensen J

et al.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345: 870-878.

43.

Okene IS

Houston-Miller NH.

Cigarette smoking, cardiovascular disease, and stroke. Circulation. 1997;96: 3243-3247.

44.

Al-Delaimy WK

Manson JE

Solomon CG

et al.

Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med. 2002;162: 273-279.

45.

Voudris V

Alexopoulos E

Karyofillis P

et al.

Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry—acute results and mid-term outcomes: a single center experience. J Invasive Cardiol. 2005;17: 401-405.

46.

Joplin Diabetes Center

. Diabetes among Asian-American versus foreign-born Asians. Available at: www.joslin.harvard.edu/api/why-commons//html.

47.

Hunt SA

Abraham WT

Chin MH

et al.

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol. 2005;46: 1116-1143.

48.

Lustman PJ

Anderson RJ

Freedland KE

et al.

Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23: 934-942.

49.

Rosenthal MJ

Fajardo M

Gilmore S

et al.

Hospitalization and mortality of diabetes in older adults: a 2-year prospective study. Diabetes Care. 1998;21: 231-235.

50.

Egede LE.

Effect of comorbid chronic diseases on prevalence and odds of depression in adults with diabetes. Psychosom Med. 2005;67: 46-51.

51.

Egede LE.

Diabetes, major depression, and functional disability among U.S. adults. Diabetes Care. 2004;27: 421-428.

52.

Montano CB.

Recognition and treatment of depression in the primary care setting. J Clin Psychiatry. 1994;55(suppl 12): 18-34.

53.

ACE Consensus Development Guidelines

. ACE consensus development conference on guidelines for glycemic control. Endocr Pract. 2001;8(suppl 1): 5-11.